Commission Regulation (EU) 2017/1510 of 30 August 2017 amending the Appendices to Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards CMR substances (Text with EEA relevance. )

Article 1

Annex XVII to Regulation (EC) No 1907/2006 is amended in accordance with the Annex.

Article 2

1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2.   It shall apply from the date of entry into force, with the exception of:
—
paragraphs (1), (2) and (3) of the Annex, which shall apply on 1 March 2018, and
—
paragraph (4)(a) of the Annex which shall apply on 1 March 2018 to the extent that it relates to the following substances:
bisphenol A; [phenol, dodecyl-, branched]; [phenol, 2-dodecyl-, branched]; [phenol, 3-dodecyl-, branched]; [phenol, 4-dodecyl-, branched]; [phenol, (tetrapropenyl) derivatives]; chlorophacinone (ISO); coumatetralyl (ISO); difenacoum (ISO); flocoumafen (ISO); disodium octaborate anhydrous; disodium octaborate tetrahydrate; bromadiolone (ISO); difethialone; [perfluorononan-1-oic acid, and its sodium and ammonium salts]; dicyclohexyl phthalate and triflumizole (ISO).

ANNEX

ANNEX
Annex XVII to Regulation (EC) No 1907/2006 is amended as follows:
(1)
in Appendix 2, the following entries are inserted in the table in order of the index numbers set out therein:
‘1,2-dichloropropane; propylene dichloride
602-020-00-0
201-152-2
78-87-5
e-glass microfibers of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO 2  50,0-56,0 %, Al 2 O 3  13,0-16,0 %, B 2 O 3  5,8-10,0 %, Na 2 O < 0,6 %, K 2 O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe 2 O 3 < 0,5 %, F 2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]
014-046-00-4
—
—’
(2)
in Appendix 4, the following entry is inserted in the table in order of the index number set out therein:
‘3,7-dimethylocta-2,6-dienenitrile
608-067-00-3
225-918-0
5146-66-7’
(3)
in Appendix 5,
(a)
the following entries are inserted in the table in order of the index numbers set out therein:
‘brodifacoum (ISO);
4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin
607-172-00-1
259-980-5
56073-10-0
lead powder;
[particle diameter < 1 mm]
082-013-00-1
231-100-4
7439-92-1
lead massive:
[particle diameter ≥ 1 mm]
082-014-00-7
231-100-4
7439-92-1’
(b)
the entry relating to warfarin; 4-hydroxy-3-(3-oxo-1- phenylbutyl)-coumarin is replaced by the following entry:
‘warfarin (ISO);
4-hydroxy-3-(3-oxo-1- phenylbutyl)-2H-chromen-2-one; [1]
(S)-4-hydroxy-3-(3-oxo- 1-phenylbutyl)-2-benzopyrone; [2]
(R)-4-hydroxy-3-(3-oxo- 1-phenylbutyl)-2-benzopyrone [3]
607-056-00-0
201-377-6 [1]
226-907-3 [2]
226-908-9 [3]
81-81-2 [1]
5543-57-7 [2]
5543-58-8 [3]’
(4)
in Appendix 6,
(a)
the following entries are inserted in the table in order of the index numbers set out therein:
‘tetrahydro-2-furyl-methanol; tetrahydrofurfuryl alcohol
603-061-00-7
202-625-6
97-99-4
gallium arsenide
031-001-00-4
215-114-8
1303-00-0
Tributyltin compounds, with the exception of those specified elsewhere in this Annex
050-008-00-3
—
—
1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear
607-710-00-5
271-093-5
68515-50-4
imidazole
613-319-00-0
206-019-2
288-32-4
bisphenol A; 4,4′-isopropylidenediphenol
604-030-00-0
201-245-8
80-05-7
phenol, dodecyl-, branched; [1]
phenol, 2-dodecyl-, branched; [2]
phenol, 3-dodecyl-, branched; [3]
phenol, 4-dodecyl-, branched; [4]
phenol, (tetrapropenyl) derivatives [5]
604-092-00-9
310-154-3 [1]
- [2]
- [3]
- [4]
- [5]
121158-58-5 [1]
- [2]
- [3]
210555-94-5 [4]
74499-35-7 [5]
chlorophacinone (ISO);2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione
606-014-00-9
223-003-0
3691-35-8
coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin
607-059-00-7
227-424-0
5836-29-3
difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin
607-157-00-X
259-978-4
56073-07-5
flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin
607-375-00-5
421-960-0
90035-08-8
disodium octaborate anhydrous; [1]
disodium octaborate tetrahydrate [2]
005-020-00-3
234-541-0 [1]
234-541-0 [2]
12008-41-2 [1]
12280-03-4 [2]
bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2 H -chromen-2-one
607-716-00-8
249-205-9
28772-56-7
difethialone (ISO);
3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2 H -1-benzothiopyran-2-one
607-717-00-3
—
104653-34-1
perfluorononan-1-oic acid [1]
and its sodium [2]
and ammonium [3] salts
607-718-00-9
206-801-3 [1]
- [2]
- [3]
375-95-1 [1]
21049-39-8 [2]
4149-60-4 [3]
dicyclohexyl phthalate
607-719-00-4
201-545-9
84-61-7
triflumizole (ISO);
(1 E )- N -[4-chloro-2-(trifluoromethyl)phenyl]-1-(1 H -imidazol-1-yl)-2-propoxyethanimine
612-289-00-6
—
68694-11-1’
(b)
the entry relating to flumioxazin (ISO); N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl)—2,H 1,4-benzoxazin-6-yl) cyclohex-1-ene-1,2dicarboxamide is replaced by the following entry:
‘flumioxazin (ISO); 2-[7-fluoro-3-oxo-4- (prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3 (2H)-dione
613-166-00-X
—
103361-09-7’

Schedules & Appendices

Cite this act